UBC and cancer: Ubiquitination has emerged as a target for cancer therapy, particularly for multiple myeloma (MM), where it has been demonstrated that UPS inhibitors (e.g., bortezomib (BTZ), carfilzomib, and ixazomib) are first‐line therapeutic agents [8, 9].